Charles Schwab Investment Management Inc Immuno Gen, Inc. Transaction History

Charles Schwab Investment Management Inc

$515 Billion
Q3 2024

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 06, 2024	BUY	$12.46 - $29.95 $770,912 - $1.85 Million	61,871 Added 3.38%	1,892,446 $56.1 Million
Q3 2023 Nov 08, 2023	BUY	$14.09 - $19.87 $283,392 - $399,645	20,113 Added 1.11%	1,830,575 $29.1 Million
Q2 2023 Aug 09, 2023	BUY	$3.75 - $20.05 $942,903 - $5.04 Million	251,441 Added 16.13%	1,810,462 $34.2 Million
Q1 2023 May 11, 2023	SELL	$3.67 - $4.92 $9,406 - $12,609	-2,563 Reduced 0.16%	1,559,021 $5.99 Million
Q4 2022 Feb 13, 2023	BUY	$4.55 - $6.31 $165,974 - $230,176	36,478 Added 2.39%	1,561,584 $7.75 Million
Q3 2022 Nov 14, 2022	BUY	$4.48 - $6.47 $272,773 - $393,938	60,887 Added 4.16%	1,525,106 $7.29 Million
Q2 2022 Aug 15, 2022	SELL	$3.15 - $5.76 $113,400 - $207,360	-36,000 Reduced 2.4%	1,464,219 $6.59 Million
Q1 2022 May 13, 2022	BUY	$4.26 - $7.48 $333,540 - $585,654	78,296 Added 5.51%	1,500,219 $7.14 Million
Q4 2021 Feb 11, 2022	BUY	$4.75 - $7.5 $75,624 - $119,407	15,921 Added 1.13%	1,421,923 $10.6 Million
Q3 2021 Nov 16, 2021	SELL	$5.02 - $6.59 $282,289 - $370,575	-56,233 Reduced 3.85%	1,406,002 $7.97 Million
Q2 2021 Aug 16, 2021	BUY	$5.79 - $8.6 $142,636 - $211,861	24,635 Added 1.71%	1,462,235 $9.64 Million
Q1 2021 May 17, 2021	BUY	$6.5 - $10.53 $1.36 Million - $2.21 Million	209,964 Added 17.1%	1,437,600 $11.6 Million
Q4 2020 Feb 16, 2021	BUY	$3.7 - $7.66 $324,353 - $671,498	87,663 Added 7.69%	1,227,636 $7.92 Million
Q3 2020 Nov 13, 2020	SELL	$3.45 - $4.89 $69,420 - $98,396	-20,122 Reduced 1.73%	1,139,973 $4.1 Million
Q2 2020 Aug 14, 2020	BUY	$3.32 - $5.34 $282,714 - $454,727	85,155 Added 7.92%	1,160,095 $5.34 Million
Q1 2020 May 15, 2020	BUY	$2.12 - $6.8 $363,463 - $1.17 Million	171,445 Added 18.98%	1,074,940 $3.67 Million
Q4 2019 Feb 07, 2020	BUY	$2.25 - $5.8 $42,547 - $109,678	18,910 Added 2.14%	903,495 $4.61 Million
Q3 2019 Nov 08, 2019	BUY	$2.22 - $3.39 $58,212 - $88,892	26,222 Added 3.05%	884,585 $2.14 Million
Q2 2019 Aug 09, 2019	BUY	$1.8 - $3.3 $43,131 - $79,074	23,962 Added 2.87%	858,363 $1.86 Million
Q1 2019 May 14, 2019	SELL	$2.41 - $5.91 $21,728 - $53,284	-9,016 Reduced 1.07%	834,401 $2.26 Million
Q4 2018 Feb 14, 2019	SELL	$3.94 - $9.7 $111,974 - $275,674	-28,420 Reduced 3.26%	843,417 $4.05 Million
Q3 2018 Nov 13, 2018	BUY	$8.6 - $11.26 $910,576 - $1.19 Million	105,881 Added 13.82%	871,837 $8.26 Million
Q2 2018 Aug 08, 2018	BUY	$9.52 - $12.15 $2.24 Million - $2.85 Million	234,880 Added 44.23%	765,956 $7.45 Million
Q1 2018 May 07, 2018	BUY	$6.7 - $12.95 $54,350 - $105,050	8,112 Added 1.55%	531,076 $5.59 Million
Q4 2017 Jan 17, 2018	BUY	$5.07 - $7.92 $413,301 - $645,630	81,519 Added 18.47%	522,964 $3.35 Million
Q3 2017 Nov 13, 2017	BUY	$5.4 - $8.47 $2.38 Million - $3.74 Million	441,445	441,445 $3.38 Million

Others Institutions Holding IMGN

# of Institutions

Shares Held

1.41M

Call Options Held

Put Options Held

View Full List

About ImmunoGen, Inc.

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

More about IMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account